NMPA Oncology Drugs China 2026 Guide

2026 List of Approved Oncology Drugs in China (NMPA Guide) and Practical Reference for Overseas Procurement

In recent years, China’s oncology field has developed rapidly, with the National Medical Products Administration (NMPA) accelerating the approval of innovative drugs. This progress provides more treatment options for cancer patients and research teams worldwide. As of 2026, China has approved numerous high-level targeted therapies, immunotherapies, and antibody-drug conjugates (ADCs), some of which are at or near international cutting-edge standards.

Hong Kong-based professional oncology drug supplier, DengYueMed, has compiled a comprehensive list of currently approved oncology drug categories and representative products under NMPA, providing practical procurement guidance for overseas medical institutions and research teams.

1. Major Categories of NMPA-Approved Oncology Drugs in China (2026)

1.1 Targeted Therapy Drugs

  • Trastuzumab and next-generation HER2-targeted therapies: for HER2-positive breast and gastric cancers
  • Afatinib, Osimertinib: for EGFR-mutated non-small cell lung cancer
  • Olaparib, Niraparib: for BRCA-mutated ovarian, breast, and prostate cancers
  • Entrectinib, Larotrectinib: for NTRK fusion solid tumors

1.2 Immune Checkpoint Inhibitors (PD-1/PD-L1 inhibitors)

  • Nivolumab, Pembrolizumab
  • Domestic PD-1 inhibitors: Sintilimab, Camrelizumab, Tislelizumab, approved for multiple solid tumors

1.3 Antibody-Drug Conjugates (ADCs)

  • T-DM1 (Trastuzumab emtansine)
  • Fam-trastuzumab deruxtecan (Enhertu)
  • Other emerging ADCs: rapidly approved, covering breast and gastric cancers

1.4 Traditional Chemotherapy and Supportive Medications

  • Chemotherapy drugs: Cisplatin, Carboplatin, Docetaxel, Paclitaxel, etc.
  • Supportive medications: bone marrow protection agents, antiemetics, etc.

Note: Indications and latest approval status should be verified on the official NMPA website. Some drugs may have updated or expanded indications.

2. Common Challenges for Overseas Procurement of Chinese Oncology Drugs

Overseas physicians and research teams often encounter the following difficulties when procuring oncology drugs from China:

  • Complex export regulations: documentation must comply with both Chinese and destination-country regulations
  • High customs clearance risk: incomplete documents may lead to delays or detention
  • Strict cold-chain requirements: biologics and ADCs are highly temperature-sensitive
  • Unstable suppliers: difficulty ensuring authenticity and consistent quality

These issues can delay research progress and affect patient treatment timelines.

3. DengYueMed: A Trusted Chinese Oncology Drug Supplier for Overseas Clients

To address these challenges, more overseas medical institutions and research teams are choosing DengYueMed.

As a Hong Kong Department of Health-certified pharmaceutical wholesaler, DengYueMed provides compliant, efficient, and secure oncology drug supply services:

  • Full compliance assurance: legal export channels with strict regulatory adherence
  • Professional cold-chain logistics: full temperature-controlled transport for biologics and ADCs
  • Real-time tracking and efficient delivery: end-to-end visibility and documentation support
  • Authenticity guarantee: supply of officially approved NMPA drugs with professional consultation

Feedback from overseas research teams shows that working with DengYueMed significantly reduces procurement risks and improves operational efficiency.

4. Summary and Practical Recommendations

By 2026, China’s NMPA-approved oncology drugs cover targeted therapies, immunotherapies, ADCs, and other advanced treatments, supporting global clinical and research needs.

For overseas procurement, selecting a compliant and experienced partner is essential. DengYueMed, with its Hong Kong certification, global logistics capabilities, and oncology specialization, has become a preferred partner for many international clients.

Practical Tip:
Before procurement, verify the latest NMPA approval status, confirm cold-chain requirements, and prepare all necessary documentation. For tailored support, contact DengYueMed for professional solutions.

This site uses Just the Docs, a documentation theme for Jekyll.